Background/aim: This study aimed to evaluate the prognostic value of modified geriatric nutritional risk index (mGNRI) in patients with unresectable/recurrent esophageal cancer (EC).
Patients And Methods: We included 143 patients aged >65 years with unresectable/recurrent EC. The mGNRI was calculated as (1.
Background: The prognosis of recurrent and unresectable gastric cancer remains poor despite the development of multidisciplinary treatments. Ramucirumab (RAM) has been proven effective against unresectable or recurrent gastric cancer. However, its administration is often discontinued because of adverse events, including hypertension and proteinuria.
View Article and Find Full Text PDF